Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial
Top Cited Papers
- 28 February 2018
- journal article
- research article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 19 (4), 497-509
- https://doi.org/10.1016/s1470-2045(18)30111-6
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trialThe Lancet Oncology, 2014
- Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysisThe Lancet, 2014
- Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline UpdateJournal of Clinical Oncology, 2013
- Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular SubtypesClinical Cancer Research, 2013
- Trapping of PARP1 and PARP2 by Clinical PARP InhibitorsCancer Research, 2012
- Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer SubtypesJournal of Clinical Oncology, 2012
- Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast CancerJournal of Clinical Oncology, 2010
- ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor ModelsClinical Cancer Research, 2007
- The Therapeutic Potential of Poly(ADP-Ribose) Polymerase InhibitorsPharmacological Reviews, 2002
- Poly(ADP-ribose) polymerase: killer or conspirator? The ‘suicide hypothesis’ revisitedTrends in Pharmacological Sciences, 2002